Core Insights - Allogene Therapeutics, Inc. will report its fourth quarter and full year 2024 financial results on March 13, 2025, followed by a live audio webcast and conference call [1] Company Overview - Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, focusing on the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseases [4] - The company aims to create a pipeline of "off-the-shelf" CAR T cell product candidates to provide readily available cell therapy on-demand, more reliably, and at greater scale to patients [4] Conference Call Details - The conference call will take place at 2:00 p.m. PT/5:00 p.m. ET, and a listen-only webcast will be available on the company's website [1][2] - Registration is required for those who wish to ask questions during the conference call, and participants will receive a personal PIN upon registration [3]
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update